Published in J Clin Invest on April 01, 2003
Osteoporosis: now and the future. Lancet (2011) 5.81
Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest (2005) 5.19
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest (2003) 2.37
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 2.08
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Effects of obesity on bone metabolism. J Orthop Surg Res (2011) 2.06
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging (2010) 1.69
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun (2015) 1.63
NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest (2009) 1.52
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol (2013) 1.48
Control of RANKL gene expression. Bone (2009) 1.47
Estrogen and the skeleton. Trends Endocrinol Metab (2012) 1.46
Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int (2005) 1.40
Osteoporosis, inflammation and ageing. Immun Ageing (2005) 1.40
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int (2012) 1.29
Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res (2012) 1.29
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int (2007) 1.26
Update on estrogens and the skeleton. J Clin Endocrinol Metab (2010) 1.25
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol (2007) 1.15
Green tea and bone metabolism. Nutr Res (2009) 1.12
Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci (2012) 1.12
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Physiology of bone loss. Radiol Clin North Am (2010) 1.09
Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface (2009) 1.06
Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet (2008) 1.06
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest (2011) 1.05
Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem (2009) 1.05
The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int (2005) 1.05
Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol (2013) 1.04
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog (2014) 1.03
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone (2008) 1.01
RANKing c-Jun in osteoclast development. J Clin Invest (2004) 1.01
Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis. J Biol Chem (2010) 1.00
Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab (2012) 0.99
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone (2011) 0.98
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
Osteoclasts: New Insights. Bone Res (2013) 0.97
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochem Med (Zagreb) (2013) 0.97
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis (2011) 0.96
Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. Calcif Tissue Int (2009) 0.95
Regulation of bone turnover by sex steroids in men. J Bone Miner Res (2008) 0.95
Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoS One (2009) 0.95
Pathophysiology of osteoporosis. Wien Med Wochenschr (2009) 0.95
HIV and bone metabolism. Discov Med (2011) 0.95
How B cells influence bone biology in health and disease. Bone (2010) 0.94
Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem (2013) 0.94
Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice. J Cell Biochem (2012) 0.94
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine (2015) 0.93
Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci U S A (2004) 0.93
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets (2010) 0.92
Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res (2009) 0.92
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int (2015) 0.92
Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int (2007) 0.92
Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J (2012) 0.92
Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int (2010) 0.91
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. Bone (2009) 0.90
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Microdamage repair and remodeling requires mechanical loading. J Bone Miner Res (2010) 0.89
Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective. Patholog Res Int (2011) 0.89
Therapeutic implications of osteoprotegerin. Cancer Cell Int (2009) 0.89
Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol (2005) 0.88
RANK ligand and the regulation of skeletal remodeling. J Clin Invest (2003) 0.88
Immunology of Osteoporosis: A Mini-Review. Gerontology (2015) 0.88
Bone loss in surgically ovariectomized premenopausal women is associated with T lymphocyte activation and thymic hypertrophy. J Investig Med (2013) 0.87
Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab (2007) 0.87
Identification of genes for complex diseases using integrated analysis of multiple types of genomic data. PLoS One (2012) 0.86
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int (2011) 0.86
The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice. Elife (2015) 0.86
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol (2011) 0.85
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes (2006) 0.85
The G-protein-coupled receptor GPR103 regulates bone formation. Mol Cell Biol (2006) 0.85
T-cells and B-cells in osteoporosis. Curr Opin Endocrinol Diabetes Obes (2014) 0.84
Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos Int (2009) 0.84
The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab (2007) 0.83
Interactions between the immune system and bone. World J Orthop (2011) 0.83
Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS One (2010) 0.83
Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. J Cell Biochem (2010) 0.83
Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther (2007) 0.82
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev (1999) 7.06
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev (2000) 6.42
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp (1988) 4.94
Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 4.47
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood (1994) 3.04
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res (1996) 2.73
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A (2000) 2.20
Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab (2002) 1.96
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res (2000) 1.91
Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17 beta-estradiol. J Clin Invest (2001) 1.68
Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem (2000) 1.68
Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab (2002) 1.61
Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res (1999) 1.52
Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest (1994) 1.51
Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J Bone Miner Res (1999) 1.44
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology (2000) 1.43
The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res (2002) 1.41
Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol (2002) 1.40
Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res (1999) 1.33
Correlates of osteoprotegerin levels in women and men. Osteoporos Int (2002) 1.31
Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology (1991) 1.25
Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res (2000) 1.20
17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology (2001) 1.19
The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res (2001) 1.15
Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology. J Bone Miner Res (2001) 1.09
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone (2002) 1.01
Development and characterization of a conditionally transformed adult human osteoblastic cell line. J Bone Miner Res (1996) 0.98
Formation of osteoblast-like cells from human mononuclear bone marrow cultures. APMIS (1991) 0.88
Osteoclast differentiation and activation. Nature (2003) 18.59
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA (2003) 2.81
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res (2002) 1.81
Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am (2005) 1.80
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab (2002) 1.61
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood (2002) 1.58
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol (1985) (2008) 1.49
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res (2004) 1.43
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res (2010) 1.32
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res (2003) 1.28
Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int (2005) 1.27
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. Ann Biomed Eng (2010) 1.26
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res (2005) 1.24